[Skip to Navigation]
December 2018

Getting to Zero HIV Among Youth: Moving Beyond Medical Sites

Author Affiliations
  • 1Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles
JAMA Pediatr. 2018;172(12):1117-1118. doi:10.1001/jamapediatrics.2018.3672

Dramatic advances have occurred in biomedical treatments for both preventing and treating HIV infection. Adherence to antiretroviral therapies (ARV) improves the health and longevity of people living with HIV and reduces the lifetime risk of transmitting HIV by up to 96%.1 Additionally, preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP)—preventive strategies that involve taking ARV medications before or immediately after potential HIV exposure—have been shown to be effective in preventing HIV infection among persons at high-risk of acquiring HIV. Given these breakthroughs, the number of people living with HIV has declined 8% from 2010 to 2015,1 leading policy makers in many states and counties to join the Getting to Zero initiative to end the transmission of HIV infection.

Add or change institution